Location of Repository

The influence of genetic variation in thirty selected genes on the clinical characteristics of early onset breast cancer

By William Tapper, Victoria Hammond, Sue Gerty, Sarah Ennis, Peter Simmonds, Andrew Collins, Diana Eccles and Posh Steering Group

Abstract

Introduction: common variants that alter breast cancer risk are being discovered. Here, we determine how these variants influence breast cancer prognosis, risk and tumour characteristics.<br/><br/>Methods: we selected 1,001 women with early onset nonfamilial invasive breast cancer from the Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH) cohort and genotyped 206 single nucleotide polymorphisms (SNPs) across 30 candidate genes. After quality control, 899 cases and 133 SNPs remained. Survival analyses were used to identify SNPs associated with prognosis and determine their interdependency with recognized prognostic factors. To identify SNPs that alter breast cancer risk, association tests were used to compare cases with controls from the Wellcome Trust Case Control Consortium. To search for SNPs affecting tumour biology, cases were stratified into subgroups according to oestrogen receptor (ER) status and grade and tested for association.<br/><br/>Results: we confirmed previous associations between increased breast cancer risk and SNPs in CASP8, TOX3 (previously known as TNRC9) and ESR1. Analysis of prognosis identified eight SNPs in six genes (MAP3K1, DAPK1, LSP1, MMP7, TOX3 and ESR1) and one region without genes on 8q24 that are associated with survival. For MMP7, TOX3 and MAP3K1 the effects on survival are independent of the main recognized clinical prognostic factors. The SNP in 8q24 is more weakly associated with independent effects on survival. Once grade and pathological nodal status (pN stage) were taken into account, SNPs in ESR1 and LSP1 showed no independent survival difference, whereas the effects of the DAPK1 SNP were removed when correcting for ER status. Interestingly, effects on survival for SNPs in ESR1 were most significant when only ER-positive tumours were examined. Stratifying POSH cases by tumour characteristics identified SNPs in FGFR2 and TOX3 associated with ER-positive disease and SNPs in ATM associated with ER-negative disease.<br/><br/>Conclusions: we have demonstrated that several SNPs are associated with survival. In some cases this appears to be due to an effect on tumour characteristics known to have a bearing on prognosis; in other cases the effect appears to be independent of these prognostic factors. These findings require validatation by further studies in similar patient group

Topics: QH426, RC0254
Year: 2008
OAI identifier: oai:eprints.soton.ac.uk:69799
Provided by: e-Prints Soton

Suggested articles

Preview

Citations

  1. (2007). A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet doi
  2. (2007). A: Long-term results of tamoxifen prophylaxis for breast cancer: 96-month follow-up of the randomized IBIS-I trial. doi
  3. (2007). Asperen CJ: Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases. Breast Cancer Res doi
  4. (2005). BL: Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. Cancer Res doi
  5. (2007). Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. doi
  6. (2008). Common breast cancerpredisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. doi
  7. (2007). Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet doi
  8. (2005). Consortium: A haplotype map of the human genome. Nature doi
  9. (2007). Czene K: Is breast cancer prognosis inherited? Breast Cancer Res doi
  10. (2008). et al.: Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet doi
  11. (2005). et al.: Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res
  12. (2006). Foekens JA: Genes associated with breast cancer metastatic to bone. doi
  13. (2007). Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet doi
  14. (2007). Genome-wide association study identifies novel breast cancer susceptibility loci. Nature
  15. (1992). Incidence of invasive breast cancer by hormone receptor status from
  16. (2008). JL: Early onset of breast cancer in a group of British black women.
  17. (2008). KL: Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. doi
  18. (2006). LD: Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res doi
  19. (2006). Lodge M: Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technol Assess doi
  20. (2002). Nederlof PM: Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. Cancer Res
  21. (2008). Nevanlinna H: NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet doi
  22. (2004). Offit K: Estrogen receptor genotypes and haplotypes associated with breast cancer risk. Cancer Res
  23. (2007). PC: PLINK: a tool set for whole-genome association and population-based linkage analyses. doi
  24. (2006). RC: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA doi
  25. (2006). Rosenberg PS: Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer. Breast Cancer Res Treat doi
  26. (2007). Steering Group: Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): Study Protocol. doi
  27. (2007). Ten genes for inherited breast cancer. Cancer Cell doi
  28. (1999). The pathology of familial breast cancer: morphological aspects. Breast Cancer Res doi
  29. (2008). Tischkowitz MD: Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet doi
  30. (2007). Wellcome Trust Case Control Consortium: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.